SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENTAnd Equity Issuance Agreement • July 2nd, 2021 • Cytek BioSciences, Inc. • Laboratory analytical instruments • Delaware
This SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT (this “Agreement”) is made and entered into as of October 5, 2020 (the “Effective Date”), by and between Becton, Dickinson and Company, a New Jersey corporation having a place of business at 1 Becton Drive, Franklin Lakes, New Jersey 07417, (“BD”), and Cytek Biosciences Inc., a Delaware corporation having a place of business at 46107 Landing Parkway, Fremont, California 94538 (“Cytek”). BD and Cytek are each referred to herein as a “Party,” and collectively as the “Parties.”
SUPPLY & LICENSE AGREEMENTLicense Agreement • July 2nd, 2021 • Cytek BioSciences, Inc. • Laboratory analytical instruments • California
This Supply and License Agreement (this “Agreement”), made as of September 1, 2020 (“Effective Date”), is by and between BIOTIUM, INC. (“BIOTIUM”), a California corporation with a place of business at 46117 Landing Parkway, Fremont, CA 94538, and CYTEK BIOSCIENCES, INC., a Delaware corporation with place of business at 46107 Landing Parkway, Fremont, CA 94538 (along with its Affiliates, “LICENSEE”).
LEASE BY AND BETWEEN SNH MEDICAL OFFICE PROPERTIES TRUST, a Maryland real estate investment trust, as Landlord, AND CYTEK BIOSCIENCES, INC., a Delaware corporation, as Tenant 47215/47211 Lakeview Boulevard, Fremont, California 94538Lease • July 2nd, 2021 • Cytek BioSciences, Inc. • Laboratory analytical instruments • California
CYTEK BIOSCIENCES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 2nd, 2021 • Cytek BioSciences, Inc. • Laboratory analytical instruments • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 23rd day of October, 2020, by and among Cytek BioSciences, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 8.9 hereof.
